Clinical trial
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
NCT00143975 · University of Ulm, Other · Completed
Key facts
| NCT number | NCT00143975 |
|---|---|
| Title | Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) |
| Official title | Phase II Study on Gemtuzumab Ozogamicin in Combination With All-trans-Retinoic Acid, High-dose Cytarabine and Mitoxantrone in Patients With Primary Refractory Acute Myeloid Leukemia |
| Lead sponsor | University of Ulm, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Acute |
| Intervention type | Drug |
| Interventions | Cytarabine, Mitoxantrone, Gemtuzumab Ozogamicin, All-trans-Retinoid Acid |
| Enrollment | 95 |
| Start date | Jun 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jun 1, 2009 |
| First posted | Sep 2, 2005 |
| Last update posted | Aug 12, 2010 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: